# GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer

> **NCT07554859** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Genfleet Therapeutics (Shanghai) Inc.** · enrollment: 90 (estimated)

## Conditions studied

- NSCLC (Advanced Non-small Cell Lung Cancer)

## Interventions

- **DRUG:** ArmA:GFH375
- **DRUG:** Arm B:GFH375
- **DRUG:** Arm C:GFH375

## Key facts

- **NCT ID:** NCT07554859
- **Lead sponsor:** Genfleet Therapeutics (Shanghai) Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-20
- **Primary completion:** 2027-04-30
- **Final completion:** 2028-04-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07554859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07554859, "GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT07554859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*